Hydroquenin (Hydroxychloroquine Sulfate)

Hydroxychloroquine sulfate accumulates in acidic cellular compartments like lysosomes, raising their pH and inhibiting enzymes involved in antigen processing. This impairs presentation of auto‑antigens to T cells, modulates cytokine release, and interferes with autophagy, resulting in a dampened immune response and reduced inflammation.

The dosage of Hydroquenin is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and any concomitant therapies. Dosage regimens differ between malaria prophylaxis, acute malaria treatment, and chronic rheumatologic use, and should follow the prescriber’s instructions.

Hydroquenin falls under an unknown pregnancy category, meaning safety data are limited. It should only be used during pregnancy or lactation when the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss possible risks with the patient.

To order Hydroquenin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Hydroquenin (hydroxychloroquine) shares a similar mechanism with chloroquine but generally has a better safety profile, especially regarding retinal toxicity, due to its lower affinity for melanin‑rich tissues. Compared with newer antimalarials, it offers dual utility in rheumatology, whereas many alternatives are limited to infectious indications only.

Hydroquenin should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and direct sunlight to maintain product stability throughout its shelf life.

Hydroquenin is administered orally, typically as a tablet swallowed with water. The exact timing (e.g., with or without food) should follow the prescriber’s guidance, as food can modestly affect absorption but does not usually require dose adjustment.

The most serious adverse events include retinal toxicity, which can lead to irreversible vision loss, cardiac toxicity such as QT prolongation or cardiomyopathy, and severe hypoglycaemia, especially in patients receiving insulin or sulfonylureas. Prompt reporting of visual changes, cardiac symptoms, or unexplained low blood sugar is essential.

Hydroquenin is contraindicated in individuals with known hypersensitivity to hydroxychloroquine or related compounds. Patients with pre‑existing retinal disease, significant cardiac conduction abnormalities, or uncontrolled severe liver or kidney impairment should avoid use unless a specialist determines that benefits outweigh risks.